Mira Pharmaceuticals, Inc. 8-K Filing
Ticker: MIRA · Form: 8-K · Filed: Dec 5, 2025 · CIK: 1904286
| Field | Detail |
|---|---|
| Company | Mira Pharmaceuticals, Inc. (MIRA) |
| Form Type | 8-K |
| Filed Date | Dec 5, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $15,241,591, $7,034,658 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Mira Pharmaceuticals, Inc. (ticker: MIRA) to the SEC on Dec 5, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (nge on which registered Common Stock, $0.0001 par value per share MIRA The Nasdaq); $15,241,591 (4, by an additional aggregate amount of $15,241,591. The Company previously sold $7,034,658); $7,034,658 (15,241,591. The Company previously sold $7,034,658 of shares of Common Stock pursuant to t).
How long is this filing?
Mira Pharmaceuticals, Inc.'s 8-K filing is 2 pages with approximately 518 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 518 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-12-05 17:15:24
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share MIRA The Nasdaq
- $15,241,591 — 4, by an additional aggregate amount of $15,241,591. The Company previously sold $7,034,658
- $7,034,658 — 15,241,591. The Company previously sold $7,034,658 of shares of Common Stock pursuant to t
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex5-1.htm (EX-5.1) — 12KB
- ex5-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-25-026445.txt ( ) — 224KB
- mira-20251205.xsd (EX-101.SCH) — 3KB
- mira-20251205_lab.xml (EX-101.LAB) — 33KB
- mira-20251205_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MIRA PHARMACEUTICALS, INC. Dated: December 5, 2025 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer